Glaukos Corp. (GKOS) Tops Q4 EPS by 6c; FY16 Revenue Outlook Flat with Views
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Glaukos Corporation Announces Fourth Quarter & Full Year 2015 Financial Results
March 1, 2016 4:15 PM ESTLAGUNA HILLS, Calif.--(BUSINESS WIRE)-- Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, today announced financial results for the fourth quarter and full year ended December 31, 2015. Key highlights include:
Achieved 44% growth in net sales to $20.3 million in the fourth quarter of 2015, compared to $14.1 million in the fourth quarter of 2014. Reported 57% growth in net sales to $71.7 million for 2015, compared to $45.6 million in 2014.... More